Genomic Health, Inc.
301 Penobscot Drive
About Genomic Health, Inc.About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
404 articles with Genomic Health, Inc.
Genomic Health, Inc. Reports Continued Double-Digit Growth In Announcement Of Second Quarter 2016 Financial Results, Raises Low End Of Full-Year Test And Revenue Guidance
Genomic Health, Inc. To Announce Second Quarter 2016 Financial Results And Host Conference Call On Tuesday, August 2, 2016
Genomic Health, Inc. And Epic Sciences Announce Strategic Collaboration To Deliver Novel AR-V7 Liquid Biopsy Test To Predict Treatment Response In Metastatic Prostate Cancer
Genomic Health, Inc. Release: Nature Partner Journals Publish Five-Year Outcomes Results From SEER Registry Demonstrating Oncotype DX Accurately Identifies Early-Stage Breast Cancer Patients With Excellent Survival
ASCO2016: Genomic Health, Inc. Announces Multiple Oncotype DX Presentations At ASCO 2016 Showcasing Industry-Leading Commitment To Bringing Precision Medicine To Cancer Patients
Genomic Health, Inc. Announces Presentation Of Seven Oncotype DX Studies At The 2016 ASCO Annual Meeting, Including Additional Prospective Outcomes Analysis
Genomic Health, Inc. Announces Publication In Journal Of Clinical Oncology Demonstrating Oncotype DX Predicts Late Distant Recurrence In Breast Cancer
Genomic Health, Inc. Reports Double-Digit Revenue And Test Growth In Announcement Of First Quarter 2016 Financial Results
Genomic Health, Inc. To Announce First Quarter 2016 Financial Results And Host Conference Call On Wednesday, May 4, 2016
Genomic Health, Inc. Announces Five-Year Outcomes From International 'PlanB' Study Demonstrating The Clinical Utility Of Oncotype DX In Node-Positive And High-Risk Node-Negative Breast Cancer
Genomic Health, Inc. Release: German National Cancer Guidelines Distinguish Oncotype DX As First And Only Multi-Gene Breast Cancer Test With 1A Level Of Evidence
Genomic Health, Inc. Announces 2016 Financial Outlook And Provides 2015 Fourth Quarter And Year-End Financial Results
Genomic Health, Inc. To Announce Fourth Quarter And Year-End 2015 Financial Results And Host Conference Call On Wednesday, February 10, 2016